Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Subjects must be able to understand and agree to comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications
Subjects chronically infected with hepatitis C virus (HCV) genotype 3
Subjects who are HCV treatment-naive
Subjects who are HCV treatment-experienced (previous exposure to non-structural 5A inhibitors is prohibited)
HCV RNA ≥10,000 IU/mL at screening
You may not be if
HCV Genotypes other than genotype-3 infection; mixed genotype infections are not permitted
Liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair
Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening
Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed)
Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy
